BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 24815720)

  • 21. Selective inhibition of unfolded protein response induces apoptosis in pancreatic cancer cells.
    Chien W; Ding LW; Sun QY; Torres-Fernandez LA; Tan SZ; Xiao J; Lim SL; Garg M; Lee KL; Kitajima S; Takao S; Leong WZ; Sun H; Tokatly I; Poellinger L; Gery S; Koeffler PH
    Oncotarget; 2014 Jul; 5(13):4881-94. PubMed ID: 24952679
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.
    Bota DA; Alexandru D; Keir ST; Bigner D; Vredenburgh J; Friedman HS
    J Neurosurg; 2013 Dec; 119(6):1415-23. PubMed ID: 24093630
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ritonavir induces endoplasmic reticulum stress and sensitizes sarcoma cells toward bortezomib-induced apoptosis.
    Kraus M; Malenke E; Gogel J; Müller H; Rückrich T; Overkleeft H; Ovaa H; Koscielniak E; Hartmann JT; Driessen C
    Mol Cancer Ther; 2008 Jul; 7(7):1940-8. PubMed ID: 18645004
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rad51 Degradation: Role in Oncolytic Virus-Poly(ADP-Ribose) Polymerase Inhibitor Combination Therapy in Glioblastoma.
    Ning J; Wakimoto H; Peters C; Martuza RL; Rabkin SD
    J Natl Cancer Inst; 2017 Mar; 109(3):1-13. PubMed ID: 28376211
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Enhanced antitumor efficacy of low-dose Etoposide with oncolytic herpes simplex virus in human glioblastoma stem cell xenografts.
    Cheema TA; Kanai R; Kim GW; Wakimoto H; Passer B; Rabkin SD; Martuza RL
    Clin Cancer Res; 2011 Dec; 17(23):7383-93. PubMed ID: 21976549
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Macrophage polarization contributes to the efficacy of an oncolytic HSV-1 targeting human uveal melanoma in a murine xenograft model.
    Liu S; Zhang J; Fang S; Zhang Q; Zhu G; Tian Y; Zhao M; Liu F
    Exp Eye Res; 2021 Jan; 202():108285. PubMed ID: 33039456
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antitumor efficacy of 34.5ENVE: a transcriptionally retargeted and "Vstat120"-expressing oncolytic virus.
    Yoo JY; Haseley A; Bratasz A; Chiocca EA; Zhang J; Powell K; Kaur B
    Mol Ther; 2012 Feb; 20(2):287-97. PubMed ID: 22031239
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting proteasome enhances anticancer activity of oncolytic HSV-1 in colorectal cancer.
    Li X; Hu W; Shen J; Li M; Gong W
    Virology; 2023 Jan; 578():13-21. PubMed ID: 36434905
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The combination of proteasome inhibitors bortezomib and gambogic acid triggers synergistic cytotoxicity in vitro but not in vivo.
    Liu N; Huang H; Xu L; Hua X; Li X; Liu S; Yang C; Zhao C; Zhao C; Li S; Dou QP; Liu J
    Toxicol Lett; 2014 Jan; 224(3):333-40. PubMed ID: 24291039
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumour-specific triple-regulated oncolytic herpes virus to target glioma.
    Delwar ZM; Liu G; Kuo Y; Lee C; Bu L; Rennie PS; Jia WW
    Oncotarget; 2016 May; 7(19):28658-69. PubMed ID: 27070093
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Aurora A kinase inhibition enhances oncolytic herpes virotherapy through cytotoxic synergy and innate cellular immune modulation.
    Currier MA; Sprague L; Rizvi TA; Nartker B; Chen CY; Wang PY; Hutzen BJ; Franczek MR; Patel AV; Chaney KE; Streby KA; Ecsedy JA; Conner J; Ratner N; Cripe TP
    Oncotarget; 2017 Mar; 8(11):17412-17427. PubMed ID: 28147331
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antitumor efficacy of oncolytic HSV-1 expressing cytosine deaminase is synergistically enhanced by DPD down-regulation and EMT inhibition in uveal melanoma xenograft.
    Liu S; Zhang J; Fang S; Su X; Zhang Q; Zhu G; Zhu L; Zhao M; Liu F
    Cancer Lett; 2020 Dec; 495():123-134. PubMed ID: 32946963
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ritonavir interacts with bortezomib to enhance protein ubiquitination and histone acetylation synergistically in renal cancer cells.
    Sato A; Asano T; Ito K; Asano T
    Urology; 2012 Apr; 79(4):966.e13-21. PubMed ID: 22296623
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells.
    Chauhan D; Tian Z; Zhou B; Kuhn D; Orlowski R; Raje N; Richardson P; Anderson KC
    Clin Cancer Res; 2011 Aug; 17(16):5311-21. PubMed ID: 21724551
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel synergistic antitumor effects of rapamycin with bortezomib on hepatocellular carcinoma cells and orthotopic tumor model.
    Wang C; Gao D; Guo K; Kang X; Jiang K; Sun C; Li Y; Sun L; Shu H; Jin G; Sun H; Wu W; Liu Y
    BMC Cancer; 2012 May; 12():166. PubMed ID: 22559167
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An oncolytic herpes simplex virus vector, G47Δ, synergizes with paclitaxel in the treatment of breast cancer.
    Zeng WG; Li JJ; Hu P; Lei L; Wang JN; Liu RB
    Oncol Rep; 2013 Jun; 29(6):2355-61. PubMed ID: 23525624
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CIP2A is a target of bortezomib in human triple negative breast cancer cells.
    Tseng LM; Liu CY; Chang KC; Chu PY; Shiau CW; Chen KF
    Breast Cancer Res; 2012 Apr; 14(2):R68. PubMed ID: 22537901
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bortezomib and SAHA synergistically induce ROS-driven caspase-dependent apoptosis of nasopharyngeal carcinoma and block replication of Epstein-Barr virus.
    Hui KF; Lam BH; Ho DN; Tsao SW; Chiang AK
    Mol Cancer Ther; 2013 May; 12(5):747-58. PubMed ID: 23475956
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Aggravated endoplasmic reticulum stress as a basis for enhanced glioblastoma cell killing by bortezomib in combination with celecoxib or its non-coxib analogue, 2,5-dimethyl-celecoxib.
    Kardosh A; Golden EB; Pyrko P; Uddin J; Hofman FM; Chen TC; Louie SG; Petasis NA; Schönthal AH
    Cancer Res; 2008 Feb; 68(3):843-51. PubMed ID: 18245486
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Hsp90 inhibitor IPI-504 overcomes bortezomib resistance in mantle cell lymphoma in vitro and in vivo by down-regulation of the prosurvival ER chaperone BiP/Grp78.
    Roué G; Pérez-Galán P; Mozos A; López-Guerra M; Xargay-Torrent S; Rosich L; Saborit-Villarroya I; Normant E; Campo E; Colomer D
    Blood; 2011 Jan; 117(4):1270-9. PubMed ID: 21106982
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.